Analyses of patterns-of-failure and prognostic factors according to radiation fields in early-stage Hodgkin lymphoma
PURPOSE: Doses and volumes of radiation therapy (RT) for early stages of Hodgkin lymphoma (HL) have been reduced over the last 30 years. Combined modality therapy (CMT) is currently the standard treatment for most patients with early-stage HL. The aim of this study was to analyze the site of relapse after RT according to the extent of radiation fields.
PATIENTS AND METHODS: Between 1987 and 2011, 427 patients were treated at our institution with RT ± chemotherapy for stage-I/II HL. Among these, 65 patients who experienced a relapse were retrospectively analyzed. Most patients had nodular sclerosis histology (86 %) and stage-II disease (75.9 %). Bulky disease was present in 21 % and 56 % of patients belonged to the unfavorable risk group according to European Organization for Research and Treatment of Cancer (EORTC)/The Lymphoma Study Association (LYSA) definitions. CMT was delivered to 91 % of patients. All patients received RT with doses ranging from 20 to 45 Gy (mean = 34 ± 5.3 Gy). The involved-field RT technique was used in 59 % of patients.
RESULTS: The mean time between diagnosis and relapse was 4.2 years (range 0.3-24.5). Out-of-field relapses were suffered by 53 % of patients. Relapses occurred more frequently at out-of-field sites in patients with a favorable disease status, whereas in-field relapses were associated with bulky mediastinal disease. Relapses occurred later for favorable compared with the unfavorable risk group (3.5 vs. 2.9 years, p = 0.5). From multivariate analyses, neither RT dose nor RT field size were predictive for an in-field relapse (p = 0.25 and p = 0.8, respectively), only bulky disease was predictive (p = 0.018).
CONCLUSION: In patients with bulky disease, RT dose and RT field size were not predictive for an in-field relapse. In this subgroup of patients, chemotherapy should be intensified. We confirmed the bad prognosis of early relapses.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:193 |
|---|---|
| Enthalten in: |
Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al - 193(2017), 2 vom: 15. Feb., Seite 116-124 |
| Sprache: |
Englisch |
|---|
| Weiterer Titel: |
Untersuchung von Rezidivstellen und prognostischen Faktoren in Abhängigkeit von Bestrahlungsfeldern im Frühstadium des Hodgkin-Lymphoms |
|---|
| Beteiligte Personen: |
Krebs, Lorraine [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Combined modality therapy |
|---|
| Anmerkungen: |
Date Completed 03.04.2017 Date Revised 02.12.2018 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s00066-016-0969-9 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM261515691 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM261515691 | ||
| 003 | DE-627 | ||
| 005 | 20231224195722.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00066-016-0969-9 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0871.xml |
| 035 | |a (DE-627)NLM261515691 | ||
| 035 | |a (NLM)27316376 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Krebs, Lorraine |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Analyses of patterns-of-failure and prognostic factors according to radiation fields in early-stage Hodgkin lymphoma |
| 246 | 3 | 3 | |a Untersuchung von Rezidivstellen und prognostischen Faktoren in Abhängigkeit von Bestrahlungsfeldern im Frühstadium des Hodgkin-Lymphoms |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.04.2017 | ||
| 500 | |a Date Revised 02.12.2018 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a PURPOSE: Doses and volumes of radiation therapy (RT) for early stages of Hodgkin lymphoma (HL) have been reduced over the last 30 years. Combined modality therapy (CMT) is currently the standard treatment for most patients with early-stage HL. The aim of this study was to analyze the site of relapse after RT according to the extent of radiation fields | ||
| 520 | |a PATIENTS AND METHODS: Between 1987 and 2011, 427 patients were treated at our institution with RT ± chemotherapy for stage-I/II HL. Among these, 65 patients who experienced a relapse were retrospectively analyzed. Most patients had nodular sclerosis histology (86 %) and stage-II disease (75.9 %). Bulky disease was present in 21 % and 56 % of patients belonged to the unfavorable risk group according to European Organization for Research and Treatment of Cancer (EORTC)/The Lymphoma Study Association (LYSA) definitions. CMT was delivered to 91 % of patients. All patients received RT with doses ranging from 20 to 45 Gy (mean = 34 ± 5.3 Gy). The involved-field RT technique was used in 59 % of patients | ||
| 520 | |a RESULTS: The mean time between diagnosis and relapse was 4.2 years (range 0.3-24.5). Out-of-field relapses were suffered by 53 % of patients. Relapses occurred more frequently at out-of-field sites in patients with a favorable disease status, whereas in-field relapses were associated with bulky mediastinal disease. Relapses occurred later for favorable compared with the unfavorable risk group (3.5 vs. 2.9 years, p = 0.5). From multivariate analyses, neither RT dose nor RT field size were predictive for an in-field relapse (p = 0.25 and p = 0.8, respectively), only bulky disease was predictive (p = 0.018) | ||
| 520 | |a CONCLUSION: In patients with bulky disease, RT dose and RT field size were not predictive for an in-field relapse. In this subgroup of patients, chemotherapy should be intensified. We confirmed the bad prognosis of early relapses | ||
| 650 | 4 | |a Comparative Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Combined modality therapy | |
| 650 | 4 | |a Hodgkin Lymphoma | |
| 650 | 4 | |a Radiotherapy | |
| 650 | 4 | |a Recurrence | |
| 650 | 4 | |a Survival | |
| 700 | 1 | |a Amorin, Sandy |e verfasserin |4 aut | |
| 700 | 1 | |a Brice, Pauline |e verfasserin |4 aut | |
| 700 | 1 | |a Guillerm, Sophie |e verfasserin |4 aut | |
| 700 | 1 | |a Menard, Jean |e verfasserin |4 aut | |
| 700 | 1 | |a Hennequin, Christophe |e verfasserin |4 aut | |
| 700 | 1 | |a Quéro, Laurent |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al |d 1995 |g 193(2017), 2 vom: 15. Feb., Seite 116-124 |w (DE-627)NLM012599174 |x 1439-099X |7 nnns |
| 773 | 1 | 8 | |g volume:193 |g year:2017 |g number:2 |g day:15 |g month:02 |g pages:116-124 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00066-016-0969-9 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 193 |j 2017 |e 2 |b 15 |c 02 |h 116-124 | ||